Temporal Trends in the Use of Anticholinergic Drugs Among Older People Living in Long-Term Care Facilities in Helsinki

Show full item record



Permalink

http://hdl.handle.net/10138/312753

Citation

Aalto , U L , Roitto , H-M , Finne-Soveri , H , Kautiainen , H & Pitkälä , K H 2020 , ' Temporal Trends in the Use of Anticholinergic Drugs Among Older People Living in Long-Term Care Facilities in Helsinki ' , Drugs & Aging , vol. 37 , no. 1 , pp. 27-34 . https://doi.org/10.1007/s40266-019-00720-6

Title: Temporal Trends in the Use of Anticholinergic Drugs Among Older People Living in Long-Term Care Facilities in Helsinki
Author: Aalto, Ulla L.; Roitto, Hanna-Maria; Finne-Soveri, Harriet; Kautiainen, Hannu; Pitkälä, Kaisu H.
Contributor: University of Helsinki, Department of General Practice and Primary Health Care
University of Helsinki, Department of General Practice and Primary Health Care
University of Helsinki, Department of General Practice and Primary Health Care
University of Helsinki, University Management
Date: 2020-01
Language: eng
Number of pages: 8
Belongs to series: Drugs & Aging
ISSN: 1170-229X
URI: http://hdl.handle.net/10138/312753
Abstract: Background The use of drugs with anticholinergic properties (DAPs) is common among older adults despite their known adverse effects, such as cognitive decline. Professionals should pay attention to DAPs, since evidence on their adverse effects has been accumulating during the last decade. However, to our knowledge previous studies exploring temporal trends in the use of DAPs are scarce. Objective The aim of this study was to assess temporal trends in the use of DAPs from 2003 to 2017 in long-term care facilities in Helsinki. Methods Four cross-sectional studies were conducted in 2003, 2007, 2011, and 2017. Participants included older people (>= 65 years) living in nursing homes (NHs) in 2003 (n = 1979), 2011 (n = 1568), and 2017 (n = 750), and in assisted living facilities (ALFs) in 2007 (n = 1336), 2011 (n = 1556), and 2017 (n = 1673) in Helsinki, Finland. Data on demographics, medication use, and diagnoses were collected by structured questionnaires. The assessments were conducted as a point prevalence over 1 day. The use of DAPs and the total anticholinergic burden were defined by the Anticholinergic Risk Scale (ARS). Results In ALFs, there has been an increasing trend in the use of DAPs over a 10-year period (41.2% in 2007 and 53.7% in 2017). In NHs, by contrast, the use of DAPs remained quite stable (52.3% in 2003 and 52.4% in 2017). The burden of DAPs measured by ARS score decreased in NHs and remained stable in ALFs. Marked changes occurred in the DAPs used; antidepressants, especially mirtazapine, increased in both settings, whereas the use of hydroxyzine and urinary antispasmodics nearly disappeared. The proportion of users of DAP antipsychotics increased in ALFs. Participants with dementia had a lower anticholinergic burden than those without dementia, in both settings. Conclusions Despite increased knowledge of the harms of DAPs, they remain widely used. Physicians seem to be aware of the harms of DAPs among people with dementia, and some other favorable trends in prescribing were also observed. Clinicians should especially consider the indications behind the use of DAP antidepressants and antipsychotics, and carefully weigh their potential benefits and harms.
Subject: CROSS-SECTIONAL ANALYSIS
NURSING-HOME RESIDENTS
MEDICATIONS
BURDEN
SCALE
BENEFICIARIES
PRESCRIPTION
ASSOCIATION
MORTALITY
DEMENTIA
3121 General medicine, internal medicine and other clinical medicine
317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Aalto2020_Artic ... TrendsInTheUseOfAntich.pdf 670.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record